{"id":"W4282922206","doi":"10.1016/j.annonc.2022.05.517","title":"Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","year":2022,"lang":"en","type":"erratum","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Oncology; Phases of clinical research; Metastatic melanoma; Basal cell; Expanded access; Internal medicine; Clinical trial; Dermatology; Surgery; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004636181,0.001332766,0.001356899,0.001622485,0.001293554,0.002443416,0.001687032,0.004009579,0.1445859],"category_scores_gemma":[0.03959497,0.0006973775,0.001476215,0.001265614,0.0008680212,0.001188364,0.000869328,0.005391838,0.0645535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002876501,"about_ca_system_score_gemma":0.003322019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007623158,"about_ca_topic_score_gemma":0.0117078,"domain_scores_codex":[0.9972012,0.0007310705,0.0004370357,0.0002912585,0.001100554,0.0002390004],"domain_scores_gemma":[0.9824709,0.006040302,0.001135464,0.0009138802,0.00831233,0.001127101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004575695,0.00001005633,0.00003627708,0.00008773015,0.000006726591,0.00005772329,0.000004362989,0.00001327879,0.00002267963,0.0001585189,0.9946175,0.004939327],"study_design_scores_gemma":[0.0002405833,0.00008668964,0.000662616,0.0003367664,0.00006296896,0.0003545754,0.00001906661,0.0001629487,0.0003809426,0.0006352559,0.9970376,0.00001997314],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.000354315,0.002388874,0.001615397,0.1061192,0.8654054,0.0003008148,0.004464055,0.000926817,0.01842509],"genre_scores_gemma":[0.01173202,0.007823549,0.006854293,0.1907474,0.2854162,0.0008658621,0.008834119,0.001793243,0.4859333],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.1445859,"threshold_uncertainty_score":0.4836879,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1218256232658172,"score_gpt":0.4326201249267309,"score_spread":0.3107945016609137,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}